Thursday, August 1, 2013

Takeda's DPP-IV Alogliptin (Nesina) gets SFDA approval in China

Takeda DPP-IV is the fifth DPP-IV inhibitor to have been approved in China. The approved ones include Sitagliptin, Vildagliptin, Linagliptin and Saxagliptin. Sanofi and Takeda have entered into an agreement to  copromote Takeda's DPP-IV inhibitor Alogliptin in China.  As per the terms of the agreement, Sanofi will have the exclusive right to promote the drug in certain defined territories in China.


Enter your email address:


Delivered by FeedBurner